<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416661</url>
  </required_header>
  <id_info>
    <org_study_id>LP 06-2018</org_study_id>
    <nct_id>NCT02416661</nct_id>
  </id_info>
  <brief_title>Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease</brief_title>
  <acronym>LYSO-PROOF</acronym>
  <official_title>Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, epidemiological study to demonstrate the correlation and
      predictive value of lyso-Gb1 concentration with the clinical severity of na誰ve, initially
      non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1
      patients and to correlate lyso-Gb1 concentration with the clinical improvement of ERT or SRT
      treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gaucher disease is an autosomal recessive inherited lysosomal storage disorder. The disease
      is caused by the hereditary deficiency of the glucocerebrosidase, a lysosomal enzyme that
      breaks down glucocerebroside into glucose and ceramide.

      To date a definitive diagnosis of Gaucher's disease can only be made applying biochemical
      testing measuring the reduced enzymatic activity of the beta-glucosidase together with
      genetic confirmation. Since numerous different mutations may be the cause of a particular
      lysosomal storage disease the sequencing of the entire beta-glucosidase gene is applied in
      Gaucher's disease in order to confirm the genetic diagnosis.

      The use of primary storage molecules as biomarker was assessed for glucosylceramide (Gb1) in
      plasma of Gaucher's disease patients and compared to the level of Gb1 in healthy individuals.

      In order to establish a sensitive and specific biomarker for GD, we compared mass spectra of
      the plasma of healthy controls and GD patients using HPLC and tandem mass spectrometry. Mass
      spectra that differed most between patients and controls were analysed in more detail. The
      resulting biomarker, which was patented in June 2011 (PCT/EP2012/002409), was lyso - Gb1. We
      identified this compound as a reliable, sensitive and specific biomarker for GD in a cohort
      of GD patients. Furthermore, in a pilot study we evaluated whether lyso-Gb1 is related to the
      specific genotypes and is reliable for long-term monitoring of the efficiency of therapy.

      The aim this study is therefore to investigate lyso-Gb1 as a long-term prognostic marker in
      na誰ve, non-ERT/SRT GD type 1 patients by monitoring over the course of 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrating the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of na誰ve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients</measure>
    <time_frame>48 month</time_frame>
    <description>lyso-Gb1 will be analzyed via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlating lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3.</measure>
    <time_frame>48 month</time_frame>
    <description>lyso-Gb1 will be analysed over a period of 36 months via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) to demonstrate the course of the biomarker.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Gaucher Disease</condition>
  <condition>Sphingolipidoses</condition>
  <arm_group>
    <arm_group_label>Participants diagnosed with Gaucher disease</arm_group_label>
    <description>Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard速)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients aged 6 months or older with genetically confirmed diagnosis of
        Gaucher disease type 1 without treatment prior to enrollment or no treatment for more than
        24 months ago
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 6 months or older

          -  Patients with genetically confirmed diagnosis of Gaucher disease type 1

          -  No prior treatment with enzyme replacement therapy or substrate reduction therapy ro
             no traetment for more than 24 months

          -  Signed informed consent by parents/legal guardian and patient

        Exclusion Criteria:

          -  Male or female patients being younger than 6 months

          -  Patients without genetically confirmed diagnosis of Gaucher disease type 1

          -  Gaucher disease 2 or 3

          -  Patient is currently undergoing enzyme replacement therapy or substrate reduction
             therapy

          -  Missing signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>volha.skrahina@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>10001</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paskal Cullufi, MD</last_name>
      <phone>+355 (0)6704507641</phone>
      <email>paskal_cullufi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Paskal Cullufi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki, Ippokration General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <phone>+30 (0)2310241845</phone>
      <email>zafeiriou@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Human Genetics</name>
      <address>
        <city>Bangalore</city>
        <zip>560100</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meenakshi Bhat, MD</last_name>
      <phone>+91 (0)9845902527</phone>
      <email>bhat.meena@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Meenakshi Bhat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103 102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Zimran, MD</last_name>
      <phone>+97 (0)226555673</phone>
      <email>azimran@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tama Dinur</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ari Zimran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children hospital</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nezha Mouane, MD</last_name>
      <phone>+21 (0)2537670294</phone>
      <email>nezhamouane@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yamna Kriouile, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Nezha Mouane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital d'Enfant</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yamna Kriouile, MD</last_name>
      <phone>+212 (0)661118292</phone>
      <email>dr.kriouile@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yamna Kriouile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital and the Institute of Child Health</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huma Cheema, MD</last_name>
      <phone>+92 (0)3009447550</phone>
      <email>pedgilahore@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Huma Cheema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge (planta 7.1)</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Solanich, MD</last_name>
      <phone>+34 (0)670449639</phone>
      <email>xsolanich@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Xavier Solanich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Greece</country>
    <country>India</country>
    <country>Israel</country>
    <country>Morocco</country>
    <country>Pakistan</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Iran, Islamic Republic of</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Tunisia</country>
    <country>United States</country>
    <country>Venezuela</country>
  </removed_countries>
  <link>
    <url>http://www.centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gaucher Disease type 1</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lipid Metabolism, Inborn Errors</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Lipidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Sphingolipidoses</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

